Bugs, Drugs, and Shrugs.
Experimental evidence "proves" that IL-17 plays a critical role in the pathogenesis of inflammatory bowel disease, but blocking IL-17 makes Crohn's disease worse.[1, 2] Only a subset of patients with melanoma benefit from checkpoint inhibitors[3] and only a subset of patients with any rheumatic disease benefit from a specific therapy. A scientist at the NIH using a rodent model can't replicate the experimental results of a scientist at Harvard. The intestinal microbiome might provide the explanation for each of these seemingly disparate conundrums.